Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Overview of Transplantation for Acute on Chronic Liver Failure

    Product not yet rated Contains 2 Component(s) Recorded On: 09/30/2019

    Webinar hosted by the Acute on Chronic Liver Failure Special Interest Group on September 30, 2019.

    In the first part of the webinar, we will provide an overview regarding the definitions of acute-on-chronic liver failure and the management of the cirrhotic patient with multi-organ system failure. In the second part, we will discuss several recent publications regarding wait list mortality and post-transplant outcomes for patients with severe acute-on-chronic liver failure. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vinay Sundaram

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

    Constantine J. Karvellas (Moderator)

    Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

  • New Insights Into the Pathogenesis and Management of Cystic Fibrosis-Related Liver Disease

    Product not yet rated Contains 2 Component(s) Recorded On: 09/24/2019

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on September 24, 2019.

    Our understanding of liver disease pathogenesis and manifestations in cystic fibrosis is evolving, as ongoing research and clinical experience expands. This webinar will provide updates on current understanding of CLFD pathogenesis, on strategies for diagnosis and monitoring, and on management of CFLD complications. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    A. Jay Freeman

    Dr. Freeman is an Associate Professor of Pediatrics in the Gastroenterology, Hepatology and Nutrition Division at Emory University and Children’s Healthcare of Atlanta. He serves as the Director of Digestive Health for the Emory Children’s Cystic Fibrosis Program and Director of the Advanced Pancreatic Care Program at CHOA. He completed his pediatric residency at the University of Mississippi’s Batson’s Children’s Hospital and received his training in pediatric gastroenterology and hepatology at Emory University.

    As part of his clinical role Dr. Freeman oversees a dedicated CF clinic that serves patients with CF experiencing GI and liver disease including evaluation for liver transplantation. He is an active member of CFLD-NET with special interest in biomarkers and elastography as modalities to determine disease progression. Additionally, he is a member of the joint NASPGHAN-ESPGHAN committee tasked on defining and classifying CFLD, serves on the NASPGHAN Pancreas and CF committee, is the GI/Liver advisor on the CF Patient Registry-PHIs linkage project, and is a national primary investigator for the CF Foundation sponsored GALAXY Study which includes 26 sites across the United States. Most recently he was the lead author on the only manuscript that addresses the multi-disciplinary approach to pre- and post-transplant care for patients with CF undergoing liver transplantation.

    Daniel H. Leung (Moderator)

    Dr. Daniel H. Leung is an Associate Professor of Pediatrics within the Division of Gastroenterology, Hepatology, and Nutrition at Baylor College of Medicine and Director of Hepatology and Liver Transplant Medicine at Texas Children’s Hospital. He is devoted to the study and care of children with chronic fibroinflammatory liver diseases, with an emphasis on cystic fibrosis related liver disease and viral hepatitis. Dr. Leung was awarded a 3-year Developing Innovative Gastroenterology Specialty Training (DIGEST) grant by the CF Foundation in 2014 to further develop clinical and research expertise in the gastroenterological and liver care of people with CF.

    He currently serves as an investigator on the steering committee of the multi-center CF Liver Disease Network where he has focused on non-invasive measures of liver fibrosis (serum biomarkers and imaging) in children with CFLD. Dr. Leung’s academic interests include the etiopathogenesis of CFLD, novel therapies to reverse liver fibrosis or portal hypertension in CF and optimizing pre and post liver transplant outcomes of children with CF and liver disease.

    Michael R. Narkewicz (Moderator)

    Michael R. Narkewicz, MD, earned his medical degree from the University of Vermont in 1983. He completed his Pediatric Residency training at the University of Colorado School of Medicine in 1986. In 1989, he completed his Fellowship in Pediatric Gastroenterology and Nutrition at the University of Colorado School of Medicine, which also included two years of research as a Pediatric Scientist Training Program Fellow in Meudon-Bellevue, France.

    Dr. Narkewicz joined the faculty of the Department of Pediatrics at the University of Colorado School of Medicine and Children’s Hospital Colorado in 1989. He was appointed Professor of Pediatrics in 2003 and was awarded tenure in 2015. He was the Medical Director of the Pediatric Liver Center from 1998-2017 and Medical Director of the Liver Transplantation Program at The Children’s Hospital from 1998-2015. He served as the Director of the Fellowship Program in Pediatric Gastroenterology from 2005 to 2013 and as the Director of Clinical Services in Pediatric Gastroenterology from 2006-2011. He was the Associate Dean for Pediatric Clinical Affairs and Associate Medical Director for Pediatric Services for the University of Colorado School of Medicine and University of Colorado Medicine from 2011-2017. He was the Medical Director for Ambulatory Care at Children’s Hospital Colorado from 2011-2018. In 2017 he was named Executive for Strategic Provider Partnerships at Children’s Hospital Colorado.

    Dr. Narkewicz is nationally recognized for his expertise in pediatric hepatology and liver transplantation. His research interests include clinical studies in children with cystic fibrosis liver disease, pediatric chronic viral hepatitis biliary atresia, Fontan associated liver disease, hematologic and immunologic complications following pediatric liver transplantation, and clinical trials in acute liver failure and cystic fibrosis liver disease. Dr. Narkewicz is Principal Investigator of the Cystic Fibrosis Liver Disease Network leading 3 studies focused on identifying markers to predict the development of advanced CF liver disease including PUSH, ELASTIC and a proteomic study.

  • HCC Staging and Treatments

    Contains 2 Component(s) Recorded On: 09/10/2019

    Webinar hosted by the Hepatology Associates Interest Group on September 10, 2019.

    This webinar will cover Barcelona Clinic Liver Cancer (BCLC) staging in hepatocellular carcinoma. Attendees will also receive an overview of curative options of surgical resection, liver transplant, and ablative techniques and noncurative options of TACE, TARE, SBRT, and systemic chemotherapy. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Vicki Shah

    Vicki Shah PA-C, MMS received a Bachelor’s of Science in Biochemistry with minor in Mathematics from California State University, Long Beach. After completing neuroscience research at UCLA, she graduated from Midwestern University in Downers Grove, IL with a Masters in Medical Sciences and Physician Assistant Studies.

    She first started in underserved internal medicine and urgent care in Southern California. She became interested in gastroenterology after caring for her father who had esophageal cancer. She practiced in gastroenterology for five years at Carle Hospital with University of Illinois in Urbana, IL. Vicki joined Hepatology at Rush University in 2016 with a strong dedication to providing education as an instructor at the PA program, national lecturer for conferences, and APP medical advisory chair for American Liver Foundation. She is active in AASLD as a member of the Associates Committee and Associates SIG. Vicki is also on the editorial board for Clinical Liver Disease multimedia journal with AASLD and a reviewer for Fundamentals of Liver Disease.

    HoChong Gilles (Moderator)

    HoChong Gilles is a board-certified Nurse Practitioner and has been working in the hepatology field since 2001. She obtained a BS in Biology and Master’s in Nursing from Virginia Commonwealth University. She graduated with a Doctorate in Nursing Practice from the University of Virginia in 2018. Her research interests include portal hypertension and liver transplantation. She is the Clinical Program Manager for Hepatology and Liver Transplant at the McGuire Veterans Affairs Medical Center in Richmond, Virginia.

    Dr. Gilles is actively engaged in professional organizations including the American Association of the Study of Liver Diseases (AASLD). She was the immediate past Chair of the Hepatology Associates Committee is the Chair of the Hepatology Associates Special Interest Group. HoChong currently serves as the President of the Virginia Council of Nurse Practitioners.

  • Palliative Care: What It Is and When To Use It

    Contains 2 Component(s) Recorded On: 08/20/2019

    Webinar hosted by the Public Health/Health Care Delivery Special Interest Group on August 20, 2019.

    Palliative care is specialized, interdisciplinary care that can be offered at any stage of a serious illness and focuses on symptom management, advance care planning, decision-making, psychosocial support, care coordination, and continuity of care. This webinar will assist clinicians in assessing basic palliative care needs in patients with liver disease as the disease progresses, offering clinical management strategies to address needs, and referring to specialty-level palliative care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lissi Hansen

    Dr. Hansen is a professor of nursing at Oregon Health and Science University. She studied nursing at Sankt Luksas Stiftelsen’s School of Nursing in Hellerup, Denmark. She received her Bachelor of Science in Nursing from Washington State University and master’s and PhD from Oregon Health and Science University. Dr. Hansen is one of the few researchers who studies patients with liver diseases including hepatocellular carcinoma (HCC) and their informal caregivers. She has an extensive clinical experience with acutely and chronically ill and dying patients and have palliative care training from the Harvard Medical School Center for Palliative Care.

    Dr. Hansen successfully co-authored and published several articles on her research as a principal investigator. She continues ongoing studies with the American Cancer Society MRSG, National Palliative Care Research Center, NIH/NINR and NIH/NCI. The long-term goal of her program of research is to develop interventions to improve symptom management and palliative care for patients with liver diseases and their families.

    Arpan Patel

    Dr. Patel is a transplant-trained hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai.

    He is currently pursuing a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA. Dr. Patel’s career goal is to ensure that patients with serious illnesses affecting the liver receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Christopher Woodrell

    Dr. Woodrell is a health services researcher and board-certified internist and palliative care physician at the Icahn School of Medicine at Mount Sinai in New York City, where he is an appointed Assistant Professor. He is also Staff Physician within the Geriatric Research, Education and Clinical Center (GRECC) at the James J. Peters VAMC in the Bronx, NY. He received his Medical Doctorate, Internal Medicine Training, and Hospice and Palliative Medicine fellowship training at Mount Sinai.

    His career goal is to help improve quality of life experienced by people facing advanced liver disease and liver cancer. His research focus is developing and testing early palliative care interventions for people with hepatocellular carcinoma and their family caregivers. He completed undergraduate training in biochemistry at Swarthmore College in Pennsylvania.

    Mina Rakoski (Moderator)

    Mina Rakoski is a Transplant Hepatologist at Loma Linda University Health. She completed her medical education at Jefferson Medical College in Philadelphia, her residency at Cedars-Sinai Medical Center in Los Angeles and her Gastroenterology and Transplant Hepatology Fellowships at University of Michigan in Ann Arbor. During her time at University of Michigan, she attained her Master of Science in Health and Health Care Research through the Rackham Graduate School.

    Dr. Rakoski has a clinical and research interest in palliative care for patients with cirrhosis and hepatocellular carcinoma. She has a dual appointment in both Gastroenterology as well as Palliative Care at Loma Linda. She has started a hepatology palliative care clinic where she is able to provide integrated hepatology and palliative care services including in-office therapeutic paracentesis for patients with advanced liver disease. She is a co-investigator on a multicenter study funded by Patient-Centered Outcomes Research Institute (PCORI), which is investigating a novel approach of integrating palliative care into subspecialty clinics. She has written several review articles on palliative care in liver disease as well as presented on this topic at national conferences.

  • HBV Reactivation: How to Approach the Immunosuppressed Patient

    Contains 2 Component(s) Recorded On: 08/08/2019

    Webinar hosted by the Hepatitis B Special Interest Group on August 8, 2019.

    This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient. The webinar will be organized as described below:

    Part 1: Management of the Cancer Patient

    Patients receiving cytotoxic chemotherapy
    Patients receiving monoclonal antibodies
    Patients undergoing hematopoietic stem cell transplant

    Part 2: Management of the Non-Cancer Patient

    Autoimmune based diseases: Rheumatologic, GI and dermatologic
    Reactivation in liver and non-liver solid organ transplantation
    HCV DAA Therapy

    We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Marina Nunez (Moderator)

    Marina Nunez, MD, PhD, is currently a Professor in the Department of Internal Medicine, sections on Infectious Diseases and on Gastroenterology at Wake Forest School of Medicine in Winston Salem, North Carolina. She received her MD and PhD from ‘Universidad de Navarra’ in Spain. She completed her Internal Medicine residency at ‘Clinica Universidad de Navarra’, and her fellowship in Infectious Diseases at Wake Forest University School of Medicine. She also obtained a degree in ‘Research Methodology and Design and Statistics in Health Sciences’. She is certified by the American Board in Internal Medicine and Infectious Diseases. She joined Wake Forest School of Medicine as faculty in 2006.

    Dr. Nunez has received several awards at her current institution for her contributions as educator, researcher and mentor. Her career has focused mainly on viral hepatitis, and she is internationally recognized for her work in HIV-co-infection. She is the author of more than 100 peer-reviewed articles, several book chapters and numerous abstracts and presentations reflecting her contribution to the field. Her expertise has led to the participation in national and international conferences, committees, and panels, as well as to the peer-review of numerous manuscripts for medical journals.

    Dr. Marina Nunez was a member of the NIH-CDC-HIVMA/IDSA Opportunistic Infections guidelines Hepatitis B Subject Group from 2010 to 2017. She currently serves on the Infectious Disease Society of America (IDSA) Standards and Practice Guidelines and on the AASLD Hepatitis B Special Interest Group's Education Subcommittee.

    Jessica Hwang

    Dr. Hwang is a professor in the Department of General Internal Medicine at The University of Texas MD Anderson Cancer Center. She has clinical and research experience in screening for and management of hepatitis B virus (HBV) in patients with cancer to facilitate early detection and interventions to reduce the risk of complications from immunosuppressive cancer therapy.

    She is a recipient of an NCI K07 Career Development Award and principal investigator of an NCI R21-funded prospective study comparing the effectiveness of widespread versus selective screening for HBV to prevent reactivation from cancer therapy; over 2000 patients were enrolled.

    She is a study chair of Southwest Oncology Group (SWOG) 1204 (PI: Scott Ramsey, MD, PhD), a national study to establish the seroprevalence of HBV, HCV, and HIV in patients with cancer at NCI Community Oncology Research Program cancer sites. She is the national PI of SWOG 1614, a multicenter randomized trial of prophylactic anti-HBV therapy in patients with HBV receiving anti-cancer therapy for solid tumors.

    Dr. Hwang is co-chair of the ASCO Provisional Clinical Opinion Committee on Hepatitis B Screening and am lead author of the panel’s 2015 updated recommendation. She is an invited member of the AASLD Hepatitis B Practice Guidelines Systematic Review and Writing Group; guideline recommendations were updated in 2015, also published guidance on HBV in 2018.

    She has published her work on screening and management of HBV in patients with cancer in Nature Reviews Gastroenterology and Hepatology, HEPATOLOGY, Journal of Clinical Oncology, Journal of Oncology Practice, among others.

    Hannah Lee

    Dr. Hannah Lee is an Assistant Professor of Medicine at Virginia Commonwealth University Medical Center in Richmond, VA in the Division of GI, Hepatology and Nutrition.

    She has a strong interest in liver cancer and viral hepatitis, particularly HBV. She was previously the Director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently Co-Director of the Multidisciplinary Liver Cancer Program at VCU and does both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Her career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic HBV. Some of her work has focused on screening and linkage to care. She has been involved in community research, education and outreach both locally and nationally in addressing liver health disparities in HBV and HCC among our various communities in the US.

    She currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

  • The 2018 Primary Biliary Cholangitis Practice Guidance: Highlights

    Product not yet rated Contains 2 Component(s) Recorded On: 07/25/2019

    Webinar recorded by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on July 25, 2019.

    In this webinar, Drs. Marlyn Mayo and Cynthia Levy will discuss the most important recommendations included in the 2018 PBC Practice Guidance document. We will utilize a prerecorded webinar format for on-demand viewing on LiverLearning®.

    Cynthia Levy

    Marlyn Mayo

  • Early Liver Transplantation in Alcoholic Hepatitis

    Contains 2 Component(s) Recorded On: 07/24/2019

    Webinar hosted by the Alcoholic Liver Disease Special Interest Group on July 24, 2019.

    Alcoholic hepatitis has high short-term mortality with limited medical therapeutic options. Liver transplantation remains controversial for this indication given inability of these patients to meet six months of sobriety. Despite emerging data on early liver transplant as salvage therapy for severe alcoholic hepatitis, barriers remain on the acceptance of this option in the routine clinical care of these patients. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Ashwani K. Singal

    Dr. Singal is an Associate Professor of Medicine at the University of South Dakota Sanford School of Medicine and Transplant Hepatologist at the Avera Transplant Institute. In addition, he also directs the hepatology elective course for the senior medical students at the Sanford Medical School and is Chief of Clinical Research Affairs at the Avera Transplant Institute. With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry.

    He has over 160 original peer reviewed articles in national and international journals and book chapters. As an active executive member of the ACG practice parameters committee, Dr. Singal has developed practice guidelines for alcoholic liver disease and vascular disorders of the liver and currently involved in writing the guidelines on nutritional management of patients with cirrhosis. He also reviews research grants and scientific research abstracts for the AGA and AASLD. Dr. Singal is currently the Secretary and the Education subcommittee Chair of the Alcoholic Liver Disease Special Interest Group at AASLD.

    Thomas Schiano (Moderator)

    Dr. Thomas D. Schiano has a clinical background in hepatology, gastroenterology and clinical nutrition. He has expertise in the management of persons with cirrhosis and other acute/chronic liver diseases, and in caring for patients prior to and after liver transplantation. Dr. Schiano has varied clinical research interests including alcohol-related liver disease, nutritional aspects of liver disease, recurrence of disease post-liver transplantation, living donor liver transplantation, and management of the complications of cirrhosis. In addition, he is involved in the care of patients pre- and post-intestinal transplant. He is a member of the liver thrombosis program, an international referral center for adults and children with difficult to diagnose and unique blood clotting disorders affecting the liver and the intestines.

    Dr. Schiano is a UNOS-certified Liver Transplant physician, and is board certified in clinical nutrition, gastroenterology and transplant hepatology. Dr. Schiano completed fellowships in Hepatology and Liver Transplantation at The Mount Sinai Hospital, Gastroenterology at Temple University Hospital, and Clinical Nutrition at Memorial Sloan-Kettering Cancer Center. He completed a residency and chief residency in internal medicine at Maimonides Medical Center.

    Dr. Schiano is Professor of Medicine, Medical Director of Adult Liver Transplantation and Director of Clinical Hepatology at the Recanati/Miller Transplantation Institute. He is also Medical Director of the Intestinal Transplant program.

  • Challenges in Antiviral Therapy for Hepatitis C

    Contains 2 Component(s) Recorded On: 07/23/2019

    Webinar hosted by the Hepatitis C Special Interest Group on July 23, 2019.

    Management of HCV after therapy has complexity if patients continue to engage in high risk activities, are at risk for advanced liver disease progression or have failed first line therapy. In addition, these complexities are especially important to consider as HCV therapy moves outside of subspecialty care. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Stuart C. Gordon

    Dr. Gordon is a Professor of Medicine at Wayne State University School of Medicine and Director, Division of Hepatology, at Henry Ford Hospital. He received his training in clinical hepatology at the University of Miami, under Drs. Leon and Eugene Schiff. His major research interest is in the epidemiology and treatment of viral hepatitis. He has authored or coauthored over 200 papers, reviews and chapters, serves on several NIH Study Sections, and serves on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee.

    In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He also serves as Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.

    Joseph Lim

    Dr. Lim is a Professor of Medicine in the Section of Digestive Diseases at Yale University, where he serves as Director of the Yale Viral Hepatitis Program. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA).

    In his role at the Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for hepatitis B, hepatitis C, and NASH. He serves on the national EPIC Gastroenterology Specialty Steering Board, the steering committee of HCV-TARGET, and on the AASLD HCV SIG Steering Committee.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP) , Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter.

    Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine. Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Nancy Reau (Moderator)

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilization. She has authored or co-authored more than 100 peer-reviewed articles, invited reviews, editorials and online programs, as well as several book chapters, and two books. She is the editor-in-chief for Clinical Liver Disease, the AASLD multimedia journal. She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.

    She is currently a member of the steering committee for the Hepatitis C Special Interest Group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

  • Evaluation of Renal Dysfunction and Hyponatremia in Patients with Cirrhosis

    Contains 2 Component(s) Recorded On: 07/09/2019

    Webinar hosted by the Clinical Practice Special Interest Group on July 9, 2019.

    This webinar will discuss the management of renal insufficiency in patients with cirrhosis, in both the inpatient and outpatient settings. Topics to be discussed include workup of the patient with acute kidney injury in the outpatient setting, management of diuretics and evaluation using novel biomarkers. The audience member will be able to understand how to balance diuretics usage to account for symptom control versus patient safety, recognize the spectrum of etiologies of kidney dysfunction in the patient with cirrhosis and how to evaluate for them, and treatment of renal failure in the inpatient setting.  We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.

    Vinay Sundaram (Moderator)

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

  • Clinical Hepatology Update On-Demand 2019

    Contains 37 Component(s), Includes Credits Recorded On: 06/14/2019

    Claim CME for the 2019 AASLD Clinical Hepatology Update.

    The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

    Core Competencies:  Patient Care and Procedural Skills Provide Patient-centered Care Values/Ethics for Interprofessional Practice Medical Knowledge Work in Interdisciplinary Teams Roles/Responsibilities Practice-based Learning and Improvement Employ Evidence-based Practice Interprofessional Communication Interpersonal and Communication Skills Apply Quality Improvement Teams and Teamwork Systems-based Practice

    Program Chairs:  Marcelo Kugelmas, MD, FAASLD Elizabeth K. Goacher, PA-C, MHS Janice Jou, MD, MHS  Lisa Catalli, MSN, NP-B

    CME Hours: 13.00 AMA PRA Category 1 Credits

    MOC Points: 13.00 MOC Points 

    Continuing Education (Nursing Credits): 13.00 Contact Hours

    Pharmacology: 1.25 Pharmacology Credits 

    All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Release Date: July 31, 2019
    Expiration Date: July 30, 2021


    Copyright: All faculty in this activity have given their permission for publication OR ©2019 AASLD

    Upon completion of this activity, learners will be able to: 

    To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
    Manage patients with complications of portal hypertension.
    Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Physician Assistants
    Transplant Coordinators
    Fellows/Trainees 

    Jasmohan Bajaj, MD, FAASLD
    Bryan Balmadrid, MD
    Stephen Caldwell, MD, FAASLD
    Lisa Catalli, MSN, NP-BC
    Michael Chang, MD, MSc, MBA, FAASLD
    Kathleen Corey, MD, MPH, MMSc
    Khashayar Farsad, MD
    Jaquelyn Fleckenstein, MD, FAASLD
    Catherine Frenette, MD
    Richard Gilroy, MD
    Robert Gish, MD, FAASLD
    Elizabeth Goacher, PA-C, MHS
    Janice Jou, MD, MHS
    Marcelo Kugelmas, MD, FAASLD
    Jennifer Lai, MD
    Anne Larson, MD, FAASLD
    Michael Leise, MD
    Cynthia Levy, MD, FAASLD
    Willscott Naugler, MD, FAASLD
    Jody Olson, MD
    Arpan Patel, MD
    Sonali Paul, MD
    K Rajender Reddy, MD, FAASLD
    Puneeta Tandon, MD, FRCPC
    Elliot Tapper, MD
    Robert Weinrieb, MD

    Disclosures

    This enduring educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Clinical Hepatology Update faculty and the Clinical Research Committee and Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.

    Faculty Disclosures
    Jasmohan Bajaj, MD, FAASLD       
    Advisory Board and/or Committee and Review Panels: Valeant, Norgine, Intercept
    Honoraria for CME Activities: Integrity CE. CLD communications
    Grants/Research Support: Valeant 

    Bryan Balmadrid, MD          
    Nothing to disclose

    Stephen Caldwell, MD, FAASLD    
    Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed, Vital Therapy

    Lisa Catalli, MSN, NP-BC    
    Nothing to disclose 

    Michael Chang, MD, MSc, MBA, FAASLD 
    Nothing to disclose 

    Kathleen Corey, MD, MPH, MMSc  
    Speaking and Teaching: Synageva
    Scientific Consulting: Novo Nordisk

    Khashayar Farsad, MD        
    Scientific Consulting: Cook Medical, Neuwave Medical 
    Grants/Research Support: Guerbet, LLC Leadership in related society: American Society of Digestive Disease Interventions (consensus panel committee) 

    Jaquelyn Fleckenstein, MD, FAASLD       
    Nothing to disclose

    Catherine Frenette, MD       
    Scientific Consulting: Bayer, Intercept; Speakers Bureau: Bayer, Gilead

    Richard Gilroy, MD  
    Speakers Bureau: Novartis, Gilead, Salix

    Robert Gish, MD, FAASLD  
    Scientific Consulting: Abbot, AbbVie, Alexion, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Contravir, Eiger, Enyo, eStudySite, Genentech, Gilead Sciences, HepaTX, HepQuant, Hoffmann-LaRoche Ltd., Intellia, Intercept, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi, Transgene
    Trimaran Leadership in related society: AbbVie, Merck, Arrowhead, Bayer, Contravir, Dova Pharmaceuticals, Eiger, Enyo, Janssen, Medimmune, Janssen/J&J, Intercept, Shionogi, Spring Bank, Ionis
    Speakers Bureau: Alexion, Bayer, BMS, Dova, Gilead Sciences Inc., AbbVie, Merck

    Elizabeth Goacher, PA-C, MHS      
    Scientific Consulting: Gilead Pharmaceuticals, AbbVie Pharmaceuticals
    Speakers Bureau: AbbVie Pharmaceticals, Gilead Pharmaceuticals

    Janice Jou, MD, MHS          
    Nothing to disclose

    Marcelo Kugelmas, MD, FAASLD  
    Speakers Bureau: Intercept, Dova, Merck, Gilead, Abbvie, Salix
    Scientific Consulting: Gilead, Abbvie, Merck, Salix, Shinogi, Dova, Intercept, Mallinkrodt 
    Grants/Research Support: Novartis, Enanta, Tobira, Pfizer, Madrigal, Genfit, Shire, Cirius, Intercept, Dova, Gilead

    Jennifer Lai, MD       
    Scientific Consulting: Third Rock Ventures, LLC, Axcella

    Anne Larson, MD, FAASLD
    Nothing to disclose

    Michael Leise, MD    
    Nothing to disclose

    Cynthia Levy, MD, FAASLD
    Grants/Research Support: Intercept, Gilead, GSK, Novartis, Genfit, CymaBay, Enanta, Arena, Durect, High Tide, Eli Lilly
    Scientific Consulting: Target Pharma Solutions, Pliant, Cara Therapeutics
    Leadership in related society: Associate Editor- Liver Transplantation

    Willscott Naugler, MD, FAASLD     
    Nothing to disclose 

    Jody Olson, MD       
    Nothing to disclose 

    Arpan Patel, MD       
    Nothing to disclose

    Sonali Paul, MD        
    Nothing to disclose 

    K Rajender Reddy, MD, FAASLD   
    Grant/Research Support: AbbVie,Gilead, Janssen, Merck, Intercept, Mallinckrodt, Conatus, Novartis 

    Puneeta Tandon, MD, FRCPC        
    Advisory Committee and/or Review Panels: Lupin Pharma Canada 

    Elliot Tapper, MD     
    Grants/Research Support: Valeant, Gilead
    Scientific Consulting: Novartis

    Robert Weinrieb, MD           
    Nothing to disclose

    Planning Committee Disclosures
    Curtis K. Argo, MD, MS, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose 

    Meena B. Bansal, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Jorge A. Bezerra, MD, FAASLD (Governing Board)
    Grant/Research Support: Shyer, Gilead 

    Mamatha Bhat (Clinical Research Committee)
    Nothing to disclose 

    Therese Bittermann, MD (Clinical Research Committee)
    Nothing to disclose

    Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
    Nothing to disclose

    Raymond Chung, MD, FAASLD (Governing Board; Maintenance of Certification Committee)
    Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
    Other: DSMB – Alnylam

    Laurie DeLeve, MD, PhD, FAASLD (Governing Board) 
    Consulting: Daiichi Sankyo; Seagen; Pfizer

    Edward Doo, MD (Clinical Research Committee) 
    Nothing to disclose

    Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
    Grants/Research Support: BMS, Gilead, Abbvie
    Consulting: Sanofi

    Kimberly A Forde, MD, MHS (Clinical Research Committee)
    Nothing to disclose 

    Michael W. Fried, MD, FAASLD (Governing Board)
    Stock/Stock Options: TARGET PharmaSolutions Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
    Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health

    Debra Guss, DNP, RN, ANP-C (Maintenance of Certification Committee)
    Nothing to disclose

    Steven K. Herrine, MD, FAASLD (Maintenance of Certification Committee)
    Grant/Research Support: Gilead, BMS, Galectin, Intercept

    Vandana Khungar, MD, MSc (Maintenance of Certification Committee)
    Nothing to disclose

    Ayman A. Koteish, MD, FAASLD (Maintenance of Certification Committee)
    Nothing to disclose

    Paul Yien Kwo, MD, FAASLD (Clinical Research Committee) 
    Consulting: Gilead, Abbvie Grants/Research Support: BMS, Abbvie 

    John R. Lake, MD, FAASLD (Governing Board)
    Consulting: Vital Therapies, SRTR
    Other: Intercept DSMB

    Jennifer Cindy Lai, MD (Clinical Research Committee)
    Consulting: Third Rock Ventures, LLC, Axcella

    Rohit Loomba, MD (Clinical Research Committee)
    Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
    Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc

    Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
    Board Membership: ACG Research Committee, Baxalta, DSMB
    Consulting: National Hemophilia Foundation 

    Lopa Mishra, MD, FAASLD (Governing Board)
    Grant/Research Support: NIH 

    Smruti R. Mohanty, MD, MS (Maintenance of Certification Committee)
    Leadership in related society: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World journal of hepatology
    Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept 

    David C. Mulligan, MD, FAASLD (Governing Board)
    Nothing to disclose 

    Arpan A. Patel, MD (Clinical Research Committee) 
    Nothing to disclose

    Heather M. Patton, MD, FAASLD (Maintenance of Certification Committee) 
    Grant/Research Support: Gilead Sciences 

    K. Gautham Reddy, MD, FAASLD (Maintenance of Certification Committee) 
    Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
    Speaker's Bureau: Intercept Dova;
    Research Grants: Merck Intercept Genfit 
    Scientific Consulting:  Advisor to Industry Commercial Enterprise, including Development of Educational Presentations: Intercept

    Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
    Nothing to disclose

    Ronald J. Sokol, MD, FAASLD (Governing Board)
    Consulting: Alexion; Albireo; Retrophin; Shire Grant/Research Support: Lumena/Shire; FFF Enterprises 

    Grace L. Su, MD, FAASLD (Maintenance of Certification Committee)
    Company Employee, Officer, Director: My husband and son have equity interest in Applied Morphomics and Prenovo

    Shikha Sundaram, MD, MSCI (Clinical Research Committee)
    Nothing to disclose

    Ryan M. Taylor, MD (Maintenance of Certification Committee)
    Speaker's Bureau: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Merck, Inc., Abbvie, Inc.
    Grant/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie, Conatus Pharmaceuticals 

    Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
    Advisory Committees and/or Review Panels: Dova
    Grant/Research Support: AbbVie, Gilead, BMS, Merck 

    Kymberly Watt, MD (Clinical Research Committee)
    Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related

    Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
    Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals

    Staff Disclosures
    Dominique Clayton 
    Nothing to disclose

    Katie Duggan, BA
    Nothing to disclose

    Janeil Klett
    Nothing to disclose

    Denise Seise
    Nothing to disclose

    Anne Wrobel 
    Nothing to Disclose 


    Acknowledgement of Financial or In-Kind Commercial Support

    No financial or in-kind commercial support was received for this educational activity.

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Credits Offered Continuing Medical Education (CME): 13.00 AMA PRA Category 1 Credits™ Maintenance of Certification (MOC): 13.00 MOC Points Continuing Education (CE): 13.00 Contact Hours Pharmacology: 1.25 Pharmacology Credits

    Accreditation and Designation Statements

    Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse Pharmacology Credits  The following presentations are also eligible for 1.25 pharmacotherapeutic hours:

    The Other Side of the Triad: Non-Cirrhotic Portal Hypertension Anticoagulation in Portal Hypertension Back to the Basics: Hepatitis B Management AIH: When to Change and If/When to Stop Therapy

    Please note onsite documentation for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board. Keep the agenda as a reference in case they have questions.

    Claiming CME Credits Physicians and other health care professionals seeking 13.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by Friday, July 30, 2021

    Claiming ABIM MOC Points Physicians seeking ABIM and or ABP MOC points must complete the CME and MOC evaluation by Friday, July 30, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

    MOC Points will be reported to the ABIM and ABP by the end of each month through August 2021 for individuals who successfully complete the MOC evaluation.

    Claiming CE Contact Hours and Pharmacology Credits
    1.    Go to http://aasld.cmecertificateonline.com
    2.    Click on the “2019 Clinical Hepatology Update” link  
    Please print all pages of your certificate for your record.
    Questions? Email Certificate@AmedcoEmail.com